Veru Inc (VERU) Stock Price, Quote & News

Company Profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle l...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 509 6897

Website: verupharma.com

Address:

2916 North Miami Avenue, Suite 1000, Miami, United States

cray1965 Jul. 20 at 10:52 PM

$VERU Hold on, guys. My bad. It says the new factory won't be completed until 2030, and Enobosarm would likely be approved and launched in, let me check........ oh, 2030. Nevermind.

0 · Reply

cray1965 Jul. 20 at 9:29 PM

$VERU Ozempic nation: America’s GLP-1 use nearly quadruples in just two years https://nypost.com/2026/07/18/health/americas-glp-1-use-nearly-quadruples-in-just-two-years/

0 · Reply

cray1965 Jul. 20 at 9:24 PM

$VERU New details revealed for Houston's $6.5B GLP-1 drug factory By Molly Wilhelm, Trending ReporterJuly 19, 2026 'New state filings this month revealed the first major steps in Eli Lilly and Company's planned $6.5 billion pharmaceutical manufacturing campus in northeast Houston, where the drugmaker expects to produce medicines including its experimental GLP-1 pill, orforglipron….The largest building detailed in the filings is a 341,505-square-foot facility designed to manufacture small-molecule medicines. Estimated to cost $193 million, the building will be larger than five football fields laid side by side.' If only Enobosarm was small molecule...wait a minute...

0 · Reply

ineedmoneybruh Jul. 20 at 2:50 PM

$VERU why so negative bruh.

0 · Reply

ineedmoneybruh Jul. 20 at 12:44 PM

$VERU offering when? they need money for the trial.

0 · Reply

cray1965 Jul. 20 at 7:13 AM

$VERU Lilly has been on an historic buying spree with its GLP windfall, but what about Novo? At JPM, Novo said they would be very aggressive in acquisitions and willing to ‘go big.’ So why very few acquisitions? They said they were shopping for acquisitions ‘complementary to their obesity assets.’ But there aren’t a lot of ‘complementary’ assets to GLPs, and Novo can’t just buy other emerging GLPs for anti-trust reasons(see Metsera). That’s too bad. All that money and nowhere to spend it. If only they could find a product complementary to their products, like maybe a drug that prevents muscle loss when used with GLPs. Or maybe a drug that could be used for maintenance after GLPs. And if it was oral that would be really cool, since they are now leading in oral. And then they could sell it next to GLPs on their DTC channels! Wow! But they would probably want something that has already been tested with Semaglutide, just to make sure it works. Oh well. Maybe just keep doing buybacks.

1 · Reply

cray1965 Jul. 19 at 4:30 AM

$VERU Veru is a distressed micro-cap with a multi-billion dollar molecule, in a pivotal trial they don’t have the money to complete. Meanwhile, Lilly is losing the oral race and if they owned Enobo they could start multiple parallel trials tomorrow with Tirzepetide, Orforglipron(Foundayo), Retatrutide; on function, incremental, maintenance, sarcopenia, BMD, while at the same time working on the co-form with Foundayo that would own the oral market for years. Lilly(or Novo) need to be bold and pay up. Veru needs to compromise and take the win.

1 · Reply

cray1965 Jul. 19 at 4:26 AM

$VERU Lilly just acquired AtaiBeckley, that has a pipeline of psychedelic-derived neuroplastogens, for 2.89B upfront. So they paid almost 3B for mushrooms. I can get those at Venice beach for $40 and they throw in a hemp bracelet. But this illustrates Veru’s particular problem. Atai was a billion dollar company and sold at a 40% premium. If Veru was a 3B company right now, with exactly the same product, it would already be sold for 4B upfront with CVRs reaching 6-8B. Veru’s upside is orders of magnitude higher than Atai, arguably with the potential to be more valuable than Lilly’s last 5 acquisitions combined, but still here we sit.

0 · Reply

Ray89c Jul. 18 at 4:18 PM

$VERU just hold and wait. Only 16mn shares. One good result or earning will blow up the roof. They are not mad to sell at the ATM offering instead of discount.

1 · Reply

cray1965 Jul. 16 at 9:33 PM

$VERU 100%. And it wouldn't even hit at the previously stated 36 weeks in May, or 34 weeks they stated in Feb(these guys can't even get the interim length straight on their own trial?) And even if they ran it all the way to 68 weeks, incremental results will be razor thin, and if you miss the 5% it's game over. That's why I think they need to make a deal before interim. Their risk adjusted value will never be higher than it is right now. BTW, if big pharma is concerned about hitting 5% or more at 68 weeks, they can just run a longer trial, say 104 weeks, and that will 100% show greater than 5% incremental weight loss. The FDA doesn't care if it's a longer trial. Geniuses.

1 · Reply

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

2026-06-04T16:45:29.000Z - 6 weeks ago

Veru pact with Novo ‘significant event,’ says Canaccord

NVO

2026-06-04T16:40:26.000Z - 6 weeks ago

Veru announces clinical supply agreement with Novo Nordisk

NVO

2026-05-15T14:08:45.000Z - 2 months ago

Veru price target lowered to $24 from $25 at Oppenheimer

May 13, 2026, 8:00 AM EDT - 2 months ago

Veru Inc. Earnings Call Transcript: Q2 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Veru Inc. Earnings release: Q2 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Veru Inc. Quarterly report: Q2 2026

May 13, 2026, 6:30 AM EDT - 2 months ago

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

May 6, 2026, 8:30 AM EDT - 2 months ago

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

2026-04-07T20:25:46.000Z - 3 months ago

Veru files $200M mixed securities shelf

2026-04-07T20:22:21.000Z - 3 months ago

Veru files to sell 23.8M shares of common stock

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Veru Inc. Registration statement: Registration filing

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Veru Inc. Registration statement: Registration filing

2026-03-09T12:35:23.000Z - 4 months ago

Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm

Mar 9, 2026, 8:30 AM EDT - 4 months ago

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Feb 26, 2026, 3:20 PM EST - 5 months ago

Veru Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 3:20 PM EST - 5 months ago

Veru Inc. Slides: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 8:00 AM EST - 5 months ago

Veru Inc. Earnings Call Transcript: Q1 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Veru Inc. Quarterly report: Q1 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Veru Inc. Earnings release: Q1 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Veru Inc. Quarterly report: Q1 2026

Feb 4, 2026, 8:30 AM EST - 5 months ago

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Jan 28, 2026, 7:00 AM EST - 6 months ago

Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2026, 7:00 AM EST - 6 months ago

Veru Inc. Proxy statement: Proxy Filing

2025-12-18T11:11:56.000Z - 7 months ago

Veru initiated with a Buy at Canaccord

Dec 17, 2025, 8:00 AM EST - 7 months ago

Veru Inc. Earnings Call Transcript: Q4 2025

Dec 17, 2025, 8:00 AM EST - 7 months ago

Veru Inc. Annual report: Q4 2025

Dec 17, 2025, 8:00 AM EST - 7 months ago

Veru Inc. Earnings release: Q4 2025

Dec 17, 2025, 6:30 AM EST - 7 months ago

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

Dec 10, 2025, 8:30 AM EST - 7 months ago

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Nov 19, 2025, 5:24 PM EST - 8 months ago

Veru Inc. Slides: Investor presentation

Oct 31, 2025, 8:30 AM EDT - 9 months ago

Veru to Present Two Abstracts at ObesityWeek 2025

2025-10-30T12:31:52.000Z - 9 months ago

Veru prices 1.4M shares at $3.00 in underwritten public offering

2025-10-30T12:26:38.000Z - 9 months ago

Veru announces pricing of $25M public offering

2025-10-29T20:14:01.000Z - 9 months ago

Veru announces offering of common stock and warrants, no amount given

Oct 29, 2025, 4:01 PM EDT - 9 months ago

Veru Announces Proposed Public Offering

2025-09-23T12:35:59.000Z - 10 months ago

Veru announces FDA meeting providing regulatory clarity for Enobosarm

Sep 23, 2025, 8:30 AM EDT - 10 months ago

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings Call Transcript: Q3 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Quarterly report: Q3 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings release: Q3 2025

Aug 12, 2025, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

2025-08-11T12:35:24.000Z - 1 year ago

Veru announces selection of modified release of enobosarm for PK study

Aug 11, 2025, 8:30 AM EDT - 1 year ago

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

2025-08-08T23:50:15.000Z - 1 year ago

Veru trading halted, news pending

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Veru Announces Reverse Stock Split

Jul 22, 2025, 8:30 AM EDT - 1 year ago

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

Jun 11, 2025, 8:30 AM EDT - 1 year ago

Veru to Participate in the Virtual BTIG Obesity Health Forum

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

May 28, 2025, 6:30 AM EDT - 1 year ago

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 9, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

May 8, 2025, 9:30 AM EDT - 1 year ago

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

May 8, 2025, 9:25 AM EDT - 1 year ago

Veru Participates in a Virtual Investor KOL Connect Segment

May 8, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings Call Transcript: Q2 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Quarterly report: Q2 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings release: Q2 2025

May 8, 2025, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 1, 2025, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Apr 16, 2025, 8:30 AM EDT - 1 year ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Feb 19, 2025, 10:41 AM EST - 1 year ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Feb 13, 2025, 8:00 AM EST - 1 year ago

Veru Inc. Earnings Call Transcript: Q1 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Veru Inc. Quarterly report: Q1 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Veru Inc. Earnings release: Q1 2025

Feb 13, 2025, 6:30 AM EST - 1 year ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Feb 11, 2025, 12:00 PM EST - 1 year ago

Veru Inc. Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Jan 28, 2025, 7:00 AM EST - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

Jan 27, 2025, 6:30 AM EST - 1 year ago

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Jan 26, 2025, 7:00 PM EST - 1 year ago

Veru Inc. Transcript: Study Result

Jan 26, 2025, 7:00 PM EST - 1 year ago

Veru Inc. Press release: Study Result

Dec 31, 2024, 8:30 AM EST - 1 year ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Dec 16, 2024, 12:00 AM EST - 1 year ago

Veru Inc. Annual report: Q4 2024

Nov 26, 2024, 8:30 AM EST - 1 year ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Nov 5, 2024, 8:30 AM EST - 1 year ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Oct 16, 2024, 8:30 AM EDT - 1 year ago

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Sep 18, 2024, 1:55 PM EDT - 1 year ago

Veru Inc. Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the 2024 Cantor Global Healthcare Conference

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings Call Transcript: Q3 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Quarterly report: Q3 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings release: Q3 2024

Aug 8, 2024, 6:30 AM EDT - 2 years ago

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Aug 1, 2024, 8:30 AM EDT - 2 years ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Jul 29, 2024, 8:30 AM EDT - 2 years ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

Jul 2, 2024, 8:30 AM EDT - 2 years ago

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Jun 24, 2024, 8:30 AM EDT - 2 years ago

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Jun 18, 2024, 4:05 PM EDT - 2 years ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Jun 17, 2024, 4:45 PM EDT - 2 years ago

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Jun 5, 2024, 11:00 AM EDT - 2 years ago

Veru Inc. Transcript: Jefferies Global Healthcare Conference

May 22, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 8:30 AM EDT - 2 years ago

Veru Announces Steven B. Heymsfield M.D.

May 14, 2024, 8:30 AM EDT - 2 years ago

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 9, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

May 9, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings Call Transcript: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Quarterly report: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings release: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Slides: Q2 2024

May 8, 2024, 6:30 AM EDT - 2 years ago

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 2, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the GLP-1 Based Therapeutics Summit

May 1, 2024, 8:30 AM EDT - 2 years ago

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

Apr 30, 2024, 8:30 AM EDT - 2 years ago

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Apr 25, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Mar 22, 2024, 4:05 PM EDT - 2 years ago

Veru Reschedules Annual Meeting of Shareholders

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Feb 27, 2024, 7:15 PM EST - 2 years ago

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

cray1965 Jul. 20 at 10:52 PM

$VERU Hold on, guys. My bad. It says the new factory won't be completed until 2030, and Enobosarm would likely be approved and launched in, let me check........ oh, 2030. Nevermind.

0 · Reply

cray1965 Jul. 20 at 9:29 PM

$VERU Ozempic nation: America’s GLP-1 use nearly quadruples in just two years https://nypost.com/2026/07/18/health/americas-glp-1-use-nearly-quadruples-in-just-two-years/

0 · Reply

cray1965 Jul. 20 at 9:24 PM

0 · Reply

ineedmoneybruh Jul. 20 at 2:50 PM

$VERU why so negative bruh.

0 · Reply

ineedmoneybruh Jul. 20 at 12:44 PM

$VERU offering when? they need money for the trial.

0 · Reply

cray1965 Jul. 20 at 7:13 AM

1 · Reply

cray1965 Jul. 19 at 4:30 AM

1 · Reply

cray1965 Jul. 19 at 4:26 AM

0 · Reply

Ray89c Jul. 18 at 4:18 PM

$VERU just hold and wait. Only 16mn shares. One good result or earning will blow up the roof. They are not mad to sell at the ATM offering instead of discount.

1 · Reply

cray1965 Jul. 16 at 9:33 PM

1 · Reply

cray1965 Jul. 16 at 9:22 PM

$VERU The primary reason Enobosarm failed the functional test in Phase 3 for Cancer wasting at GTX in 2013 is they measured improvement in stair climb power. Endpoint being ‘"Can a lung cancer patient on chemotherapy(and Enobosarm) actually climb stairs better than before?" Results were inconsistent, mainly because cancer patients are typically in a weakening state and it is hard to show functional ‘improvement.’ The genius of the Enobosarm Quality trial with GLP, is they measured the ‘rate of decline in stairclimber power.’ And Enobosarm showed 47% less decline in stairclimber power. So the endpoint measurement was wrong in the cancer trial, which not only opens the door for a potential GLP label for function, but potentially a rerun of the cancer wasting trial with a different endpoint for a possible cachexia/sarcopenia label. Also a huge billion $ indication that right now has no approved drugs. Novo, Lilly, Pfizer, Roche, AstraZeneca, Abbvie, Merck, Amgen are you listening?

0 · Reply

BioRich Jul. 16 at 8:39 PM

$GUTS Still massively bullish. #1 on our list and that doesn't appear to be changing anytime soon. Surprisingly, adding more on this pullback. Simple math...this kicks to a buck again (which I have no doubt it will...and beyond), you're up 17% on your trade. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $ALLR $ALUR $VERU

3 · Reply

mrkymrk Jul. 16 at 3:00 PM

$VERU Sounds like Mitch needs to listen to more Kenny Rogers

0 · Reply

GenralZod Jul. 16 at 12:59 PM

$VERU I'll join in with Cray. I traded GTXi for years. thru Enobosarm trials/failures. From cancer to Urinary incontinence. all failed in the end. So Mitch leaves. Joins what is now VERU. and acquires Enobosarm. Why? after all the failures would you acquire? I'd have to say Mitch knows it works. Knows it's safe. Just needed that indication. Well i'd say This is it! this is the perfect fit. His golden ticket! is the trial set up for Victory? IDK. With Steiner GTXi hit $1B cap during trials. twice over the years (and lost it all) . VERU hit $1B cap during clinical trial with Mitch here (also lost it) and now I believe history will repeat. another $1B cap coming but will it hold? I'll take my gains & hold a pinch in case ticket gets punched.

0 · Reply

mrkymrk Jul. 16 at 12:33 PM

$VERU What is VERU hoping to see at the 32 week interim analysis in Q1? I don’t see any scenario that benefits them by sharing this data. Any data they release, short of obtaining additional 5% weight loss(which isn’t possible at 32weeks), will be seen as a disappointment and cause the stock price to crater. There is ZERO upside in releasing this data! And if they didn’t learn from the last trial, investors will speculate about safety (which won’t be released during ongoing trial) so even IF there is positive news, the stock will still Crater!!!!!! Who is advising these retards?!?!?

1 · Reply

mpired Jul. 16 at 9:33 AM

$VERU I think you just answered your own question. If CEO is too emotionally invested for personal reasons, then this stock has a long way to be successful. It may be dead money until q1 2027, in slightly worse case q4 2027, and in absolute worst case something something, along the way, something something, more bad news, something something

0 · Reply

cray1965 Jul. 16 at 5:38 AM

$VERU Steiner is the wildcard in all of this. In case you don’t know- Steiner co-developed Enobosarm at GTx, Inc in the early 2000s. He had a high profile failure when Enobasarm failed a phase 3 trial for muscle wasting in cancer patients, eventually causing him to resign. When he joined Veru he bought the rights back for Enobosarm and has effectively been trying to find the right indication and regulatory path for the molecule ever since. GLP expansion provided the perfect opportunity. So this is personal for him, and he may be too emotionally invested in Veru to make a deal for less than what he thinks it is worth. Make the deal, Mitch. Take the win. Please.

0 · Reply

mrkymrk Jul. 15 at 3:41 PM

$VERU Still recruiting….. once again, Steiner over promises and under delivers…. The only way this is acceptable is if they end up enrolling significantly more than 200 patients in the trial.

1 · Reply

cray1965 Jul. 15 at 4:04 AM

$VERU I don’t think this is to fully tap the ATM to fund the trial for a few reasons 1. They could have raised more money in October to easily hit interim or even the whole trial 2. If you're fully tapping an ATM, you would have loudly promoted the Novo ROFN and opened and tapped the ATM when the price was at $4.50 , or $5 or $6( if they promoted it) Why wait a month until the stock settles to tap 3. This still doesn’t solve their enrollment problem, even by changing to 32 weeks. I personally don’t think they are close to full enrollment 4. Plateau’s primary endpoint, and big prize, is incremental weight loss at the weight loss Plateau(it’s literally in the name) Even at 36 weeks, or 34 weeks, patients are barely reaching the plateau. 32 is even worse. And no matter how great the DEX, the market will punish the stock at interim if it doesn’t show incremental. But I agree, if anyone can snatch defeat from the jaws of victory it’s Steiner. He is the wildcard, and could overplay his hand

1 · Reply

cray1965 Jul. 15 at 3:52 AM

$VERU I think they are probably tapping the ATM, but I think it is more likely a leverage play and a $ patch. Similar to reducing the interim length to 32 weeks so they can say they can hit Q12027, they are adding a few mil so they have enough $ to say they can technically last through interim.

0 · Reply

cray1965 Jul. 15 at 3:50 AM

$VERU WSJ reports today that Novo’s oral Wegovy pill is pulling ahead of Lilly’s Foundayo in early U.S. prescription volume: roughly 89% share for Novo’s oral Wegovy versus 11% for Lilly’s Foundayo, with week-ending July 3 prescriptions 153,050 for Wegovy** versus 19,550 for Foundayo.

0 · Reply

cray1965 Jul. 15 at 3:49 AM

$VERU July 14 (Reuters) - Potential signs of frailty in older adults taking Eli Lilly’s GLP-1 obesity drug Zepbound may signal relatively high risks for adverse outcomes, according to a large study that underscores concerns about how best to monitor seniors as U.S. Medicare expands access to ‌GLP-1 therapies…. The new study from U.S. data analytics firm nference focused on Zepbound because previous analyses linked tirzepatide with more weight and muscle loss than semaglutide, said Venky Soundararajan, senior author of the report that was released on Monday and ⁠has been submitted for peer review….

0 · Reply

Market Cap	38.20M
Revenue (ttm)	0.00
Net Income (ttm)	-22.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	190,500
Avg Vol	2,412,106
Day's Range	N/A - N/A
Shares Out	16.05M
Stochastic %K	6%
Beta	-1.19
Analysts	Strong Sell
Price Target	$24.50